Company Overview of Nanotherapeutics, Inc.
Nanotherapeutics, Inc. manufactures and develops biopharmaceutical products. The company is engaged in the pre-clinical and clinical development, formulation optimization, and cGMP manufacture of biopharmaceutical products and medical devices. The company develops biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infective, vaccines, and orthopedics products. It offers development, manufacturing, analytical, and collaboration services. Nanotherapeutics, Inc. has a strategic alliance with PharmAthene Inc. The company was formerly known as Nanocoat Technologies, Inc. and changed its name to Nanotherapeutics, Inc. in July 2002. The company was founded in...
13859 Progress Boulevard
Alachua, FL 32615
Founded in 1999
Key Executives for Nanotherapeutics, Inc.
Chief Executive Officer and President
Co-Founder, Director and Member of the Advisory Board
Chief Financial Officer and Director
Senior Vice President of Operations
Senior Vice President of Preclinical Development & QA and Company Secretary
Compensation as of Fiscal Year 2016.
Nanotherapeutics, Inc. Key Developments
Battelle and Nanotherapeutics Form Alliance to Speed Up Process of Industry Bringing Medical Countermeasures to Market
Apr 5 17
Battelle and Nanotherapeutics, Inc. announced that the organizations have entered an alliance to bring together core research, development, test and evaluation and manufacturing capabilities needed to expedite the development of medical countermeasures urgently required by the Department of Defense to protect deployed military forces from CBRN threats.
Trethera Corp. and Nanotherapeutics Enter Pact for Rights to Triapine in Hematological Malignancies
Jan 17 17
Trethera Corp. and Nanotherapeutics reported the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis.
Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies
Jan 5 17
Trethera Corporation and Nanotherapeutics, Inc. announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis. Trethera has advanced preclinical development of proprietary, small molecule inhibitors of deoxycytidine kinase (dCK), the rate-limiting enzyme in the salvage pathway of nucleotide biosynthesis. Results of its preclinical studies indicate robust and durable anti-leukemic activity of its dCK inhibitors when combined with inhibitors of RNR, and these combinations have demonstrated superior activity over single agent treatments. Trethera aims to commence a Phase I clinical trial for its orally administered, lead dCK inhibitor, TRE-515, in H2 2017.
Similar Private Companies By Industry
Recent Private Companies Transactions